Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Chronic deep brain stimulation in an Alzheimer's disease mouse model enhances memory and reduces pathological hallmarks.

Mann A, Gondard E, Tampellini D, Milsted JAT, Marillac D, Hamani C, Kalia SK, Lozano AM.

Brain Stimul. 2018 Mar - Apr;11(2):435-444. doi: 10.1016/j.brs.2017.11.012. Epub 2017 Nov 23.

PMID:
29246746
2.

Synaptic activity protects against AD and FTD-like pathology via autophagic-lysosomal degradation.

Akwa Y, Gondard E, Mann A, Capetillo-Zarate E, Alberdi E, Matute C, Marty S, Vaccari T, Lozano AM, Baulieu EE, Tampellini D.

Mol Psychiatry. 2018 Jun;23(6):1530-1540. doi: 10.1038/mp.2017.142. Epub 2017 Jul 11.

3.

Synaptic activity and Alzheimer's disease: a critical update.

Tampellini D.

Front Neurosci. 2015 Nov 4;9:423. doi: 10.3389/fnins.2015.00423. eCollection 2015.

4.

Methylene blue upregulates Nrf2/ARE genes and prevents tau-related neurotoxicity.

Stack C, Jainuddin S, Elipenahli C, Gerges M, Starkova N, Starkov AA, Jové M, Portero-Otin M, Launay N, Pujol A, Kaidery NA, Thomas B, Tampellini D, Beal MF, Dumont M.

Hum Mol Genet. 2014 Jul 15;23(14):3716-32. doi: 10.1093/hmg/ddu080. Epub 2014 Feb 20.

5.

PGC-1α overexpression exacerbates β-amyloid and tau deposition in a transgenic mouse model of Alzheimer's disease.

Dumont M, Stack C, Elipenahli C, Jainuddin S, Launay N, Gerges M, Starkova N, Starkov AA, Calingasan NY, Tampellini D, Pujol A, Beal MF.

FASEB J. 2014 Apr;28(4):1745-55. doi: 10.1096/fj.13-236331. Epub 2014 Jan 7.

6.

Bezafibrate administration improves behavioral deficits and tau pathology in P301S mice.

Dumont M, Stack C, Elipenahli C, Jainuddin S, Gerges M, Starkova N, Calingasan NY, Yang L, Tampellini D, Starkov AA, Chan RB, Di Paolo G, Pujol A, Beal MF.

Hum Mol Genet. 2012 Dec 1;21(23):5091-105. doi: 10.1093/hmg/dds355. Epub 2012 Aug 24.

7.

Critical role of intraneuronal Aβ in Alzheimer's disease: technical challenges in studying intracellular Aβ.

Gouras GK, Willén K, Tampellini D.

Life Sci. 2012 Dec 10;91(23-24):1153-8. doi: 10.1016/j.lfs.2012.06.004. Epub 2012 Jun 19.

8.

Intraneuronal Aβ accumulation, amyloid plaques, and synapse pathology in Alzheimer's disease.

Capetillo-Zarate E, Gracia L, Tampellini D, Gouras GK.

Neurodegener Dis. 2012;10(1-4):56-9. doi: 10.1159/000334762. Epub 2012 Jan 21.

PMID:
22269167
9.

Impaired β-amyloid secretion in Alzheimer's disease pathogenesis.

Tampellini D, Rahman N, Lin MT, Capetillo-Zarate E, Gouras GK.

J Neurosci. 2011 Oct 26;31(43):15384-90. doi: 10.1523/JNEUROSCI.2986-11.2011.

10.

High-resolution 3D reconstruction reveals intra-synaptic amyloid fibrils.

Capetillo-Zarate E, Gracia L, Yu F, Banfelder JR, Lin MT, Tampellini D, Gouras GK.

Am J Pathol. 2011 Nov;179(5):2551-8. doi: 10.1016/j.ajpath.2011.07.045. Epub 2011 Sep 15.

11.

Analysis of vesicular trafficking in primary neurons by live imaging.

Tampellini D, Gouras GK.

Methods Mol Biol. 2011;793:343-50. doi: 10.1007/978-1-61779-328-8_22.

PMID:
21913111
12.

Effects of synaptic modulation on beta-amyloid, synaptophysin, and memory performance in Alzheimer's disease transgenic mice.

Tampellini D, Capetillo-Zarate E, Dumont M, Huang Z, Yu F, Lin MT, Gouras GK.

J Neurosci. 2010 Oct 27;30(43):14299-304. doi: 10.1523/JNEUROSCI.3383-10.2010.

13.

Dysregulation of the mTOR pathway mediates impairment of synaptic plasticity in a mouse model of Alzheimer's disease.

Ma T, Hoeffer CA, Capetillo-Zarate E, Yu F, Wong H, Lin MT, Tampellini D, Klann E, Blitzer RD, Gouras GK.

PLoS One. 2010 Sep 20;5(9). pii: e12845. doi: 10.1371/journal.pone.0012845.

14.

Synapses, synaptic activity and intraneuronal abeta in Alzheimer's disease.

Tampellini D, Gouras GK.

Front Aging Neurosci. 2010 May 21;2. pii: 13. doi: 10.3389/fnagi.2010.00013. eCollection 2010.

15.

Intraneuronal beta-amyloid accumulation and synapse pathology in Alzheimer's disease.

Gouras GK, Tampellini D, Takahashi RH, Capetillo-Zarate E.

Acta Neuropathol. 2010 May;119(5):523-41. doi: 10.1007/s00401-010-0679-9. Epub 2010 Mar 31. Review.

16.

Synaptic activity reduces intraneuronal Abeta, promotes APP transport to synapses, and protects against Abeta-related synaptic alterations.

Tampellini D, Rahman N, Gallo EF, Huang Z, Dumont M, Capetillo-Zarate E, Ma T, Zheng R, Lu B, Nanus DM, Lin MT, Gouras GK.

J Neurosci. 2009 Aug 5;29(31):9704-13. doi: 10.1523/JNEUROSCI.2292-09.2009.

17.

Triterpenoid CDDO-methylamide improves memory and decreases amyloid plaques in a transgenic mouse model of Alzheimer's disease.

Dumont M, Wille E, Calingasan NY, Tampellini D, Williams C, Gouras GK, Liby K, Sporn M, Nathan C, Flint Beal M, Lin MT.

J Neurochem. 2009 Apr;109(2):502-12. doi: 10.1111/j.1471-4159.2009.05970.x. Epub 2009 Feb 7. Erratum in: J Neurochem. 2009 May;109(4):1192.. Nathan, Carl [added].

18.

Internalized antibodies to the Abeta domain of APP reduce neuronal Abeta and protect against synaptic alterations.

Tampellini D, Magrané J, Takahashi RH, Li F, Lin MT, Almeida CG, Gouras GK.

J Biol Chem. 2007 Jun 29;282(26):18895-906. Epub 2007 Apr 27.

19.

Beta-amyloid accumulation in APP mutant neurons reduces PSD-95 and GluR1 in synapses.

Almeida CG, Tampellini D, Takahashi RH, Greengard P, Lin MT, Snyder EM, Gouras GK.

Neurobiol Dis. 2005 Nov;20(2):187-98.

PMID:
16242627
20.

In vivo detection of iron and neuromelanin by transcranial sonography: a new approach for early detection of substantia nigra damage.

Zecca L, Berg D, Arzberger T, Ruprecht P, Rausch WD, Musicco M, Tampellini D, Riederer P, Gerlach M, Becker G.

Mov Disord. 2005 Oct;20(10):1278-85.

PMID:
15986424
21.

The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging.

Zecca L, Stroppolo A, Gatti A, Tampellini D, Toscani M, Gallorini M, Giaveri G, Arosio P, Santambrogio P, Fariello RG, Karatekin E, Kleinman MH, Turro N, Hornykiewicz O, Zucca FA.

Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9843-8. Epub 2004 Jun 21.

22.

The neuromelanin of human substantia nigra: structure, synthesis and molecular behaviour.

Zecca L, Zucca FA, Costi P, Tampellini D, Gatti A, Gerlach M, Riederer P, Fariello RG, Ito S, Gallorini M, Sulzer D.

J Neural Transm Suppl. 2003;(65):145-55. Review.

PMID:
12946053
23.

The neuromelanin of human substantia nigra and its interaction with metals.

Zecca L, Tampellini D, Gatti A, Crippa R, Eisner M, Sulzer D, Ito S, Fariello R, Gallorini M.

J Neural Transm (Vienna). 2002 May;109(5-6):663-72. Review.

PMID:
12111458
24.
25.

Substantia nigra neuromelanin: structure, synthesis, and molecular behaviour.

Zecca L, Tampellini D, Gerlach M, Riederer P, Fariello RG, Sulzer D.

Mol Pathol. 2001 Dec;54(6):414-8. Review.

26.

Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes.

Zecca L, Gallorini M, Schünemann V, Trautwein AX, Gerlach M, Riederer P, Vezzoni P, Tampellini D.

J Neurochem. 2001 Mar;76(6):1766-73.

27.

The structure of neuromelanin and its iron binding site studied by infrared spectroscopy.

Bridelli MG, Tampellini D, Zecca L.

FEBS Lett. 1999 Aug 20;457(1):18-22.

Supplemental Content

Loading ...
Support Center